Topics:

FDA Approves Busulfex Injection

FDA Approves Busulfex Injection

WASHINGTON—The FDA has approved Orphan Medical’s Busulfex (busulfan) Injection for use in combination with cyclophosphamide as a conditioning regimen prior to allogeneic hematopoietic progenitor cell transplantation for chronic myelogenous leukemia (CML). (See Oncology News International, February 1999, for a report on the Oncology Drugs Advisory Committee’s discussion of the agent and its recommendation to the FDA.)

 
Loading comments...

By clicking Accept, you agree to become a member of the UBM Medica Community.